NCT06769971View on ClinicalTrials.gov

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Ivonescimab

20mg/kg，IV infusion，Day1，Q3W

DRUG

Cadonilimab

10mg/kg，IV infusion，Day8，Q6W

DRUG

Etoposide

100mg/kg，IV infusion，Day1-3，Q3W

DRUG

Carboplatin

AUC 5，IV infusion，Day1，Q3W

Trial Locations (1)

Unknown

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER